The Use of Next-Generation Sequencing in Molecular Diagnosis of Neurofibromatosis Type 1: A Validation Study

Ryo Maruoka,^{1,2} Toshiki Takenouchi,^{1,3} Chiharu Torii,¹ Atsushi Shimizu,⁴ Kumiko Misu,¹ Koichiro Higasa,⁵
Fumihiko Matsuda,⁵ Arihito Ota,⁶ Katsumi Tanito,⁶ Akira Kuramochi,⁷ Yoshimi Arima,⁸ Fujio Otsuka,⁹
Yuichi Yoshida,¹⁰ Keiji Moriyama,² Michihito Niimura,⁶ Hideyuki Saya,⁸ and Kenjiro Kosaki¹

Aims: We assessed the validity of a next-generation sequencing protocol using in-solution hybridization-based enrichment to identify *NF1* mutations for the diagnosis of 86 patients with a prototypic genetic syndrome, neurofibromatosis type 1. In addition, other causative genes for classic genetic syndromes were set as the target genes for coverage analysis. **Results:** The protocol identified 30 nonsense, 19 frameshift, and 8 splice-site mutations, together with 10 nucleotide substitutions that were previously reported to be pathogenic. In the remaining 19 samples, 10 had single-exon or multiple-exon deletions detected by a multiplex ligation-dependent probe amplification method and 3 had missense mutations that were not observed in the normal Japanese SNP database and were predicted to be pathogenic. Coverage analysis of the genes other than the *NF1* gene included on the same diagnostic panel indicated that the mean coverage was 115-fold, a sufficient depth for mutation detection. **Conclusions:** The overall mutation detection rate using the currently reported method in 86 patients who met the clinical diagnostic criteria was 92.1% (70/76) when 10 patients with large deletions were excluded. The results validate the clinical utility of this next-generation sequencing-based method for the diagnosis of neurofibromatosis type 1. Comparable detection rates can be expected for other genetic syndromes, based on the results of the coverage analysis.

Introduction

GENETIC TESTING HAS HELPED clinicians to define the molecular pathology of diseases, especially when patients present with an atypical combination of phenotypic features. Our group developed a custom-designed mutation analysis panel using denaturing high-pressure liquid chromatography for the systematic screening of patients with classic genetic syndromes (Kosaki *et al.*, 2005). The system can be used to screen all the exons of the candidate gene quickly and has been helpful in confirming the clinical diagnosis, as published in a series of reports in this journal

(Udaka *et al.*, 2005, 2006, 2007; Aramaki *et al.*, 2006; Samejima *et al.*, 2007; Hattori *et al.*, 2009). Nevertheless, the throughput of the system was not high enough to screen multiple candidate genes in a single testing.

The recent advent of a target sequencing panel with the next-generation sequencing technology has enabled many genes, regardless of size, to be analyzed in a systematic and comprehensive manner, as reviewed in this journal (Yan *et al.*, 2013). The strength of such a comprehensive approach is the ability to detect atypical presentations of classic syndromes, as illustrated by our recent reports on several patients with atypical presentations of mutations in the causative

¹Center for Medical Genetics, Keio University School of Medicine, Tokyo, Japan.

²Section of Maxillofacial Orthognathics, Division of Maxillofacial/Neck Reconstruction, Department of Maxillofacial Reconstruction and Function, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.

³Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan.

⁴Division of Biomedical Information Analysis, Iwate Tohoku Medical Megabank Organization, Iwate Medical University, Iwate, Japan.

⁵Center for Genomic Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.

⁶Department of Dermatology, Jikei University School of Medicine, Tokyo, Japan.

⁷Department of Dermatology, Saitama Medical University, Saitama, Japan.

⁸Division of Gene Regulation, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan.

⁹Department of Dermatology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Japan.

¹⁰Division of Dermatology, Department of Medicine of Sensory and Motor Organs, Faculty of Medicine, Tottori University, Yonago, Japan.

genes of three classic genetic syndromes: the neonatal progeroid presentation of an *FBN1* mutation (Takenouchi *et al.*, 2013a), the Noonan-café au lait syndrome-like presentation of a *MAP2K2* mutation (Takenouchi *et al.*, 2013b), and Stickler syndrome-like presentation of *SOX9* mutation (Takenouchi *et al.*, 2014).

In this study, we assessed the analytical and clinical validity of the next-generation sequencing protocol with in-solution hybridization-based enrichment to identify disease-causing mutations in the diagnosis of a prototypic genetic syndrome, neurofibromatosis type 1, compared with direct capillary sequencing, which is the current gold standard methodology. The reason for the choice of the *NF1* gene, the causative gene for neurofibromatosis type 1, was twofold: (1) neurofibromatosis type 1 is a relatively common genetic condition with readily recognizable phenotypes: café-au-lait spots, cutaneous neurofibromas, axillary and inguinal freckling, and Lisch nodules (iris hamartomas) (Carey and Viskochil, 1999) and (2) the *NF1* gene comprised a total of 58 exons and is one of the largest genes in the human genome, making it a relatively difficult clinical target for direct capillary sequencing.

Materials and Methods

Patients

The current research protocol was approved by the institutional review board of Keio University and each participating center. Eighty-six patients with neurofibromatosis type 1 who met the NIH clinical diagnostic criteria (Neurofibromatosis Conference Statement, 1988) were recruited from multiple centers participating in the project. The NIH diagnostic criteria for neurofibromatosis type 1 defines an individual as neurofibromatosis type 1 when the person has two or more of the following features: six or more café-au-lait macules with a maximum diameter of over 5 mm in prepubertal individuals and with a maximum diameter of over 15 mm in postpubertal individuals; two or more neurofibromas of any type or 1 plexiform neurofibroma; freckling in the axillary or inguinal regions; optic glioma, two or more Lisch nodules; a distinctive osseous lesion, such as sphenoid dysplasia or tibial pseudarthrosis; and a first-degree relative (parent, sibling, or offspring) with neurofibromatosis type 1, as defined according to the above-mentioned criteria. After written consent was obtained at each participating center, the whole blood samples were sent to Keio University for genetic analysis.

Genomic DNA, sample preparation, targeted capturing, sequencing

Genomic DNA was extracted from peripheral blood according to standard procedures using the phenol–chloroform extraction method and checked for quality using Qubit (Life Technologies). The genomic DNA (3 µg) was fragmented into ~150 bp. In-solution hybridization-based enrichment was performed using the SureSelect Target Enrichment system (Agilent Technologies). The *NF1* gene (the canonical Refseq transcript NM_001042492.2) together with 108 causative genes for the more common classical congenital malformation syndromes selected from a standard textbook (Jones, 2005) was set as the target gene (Table 1). Genes that

are responsible for a disease phenotype and involved in the RAS pathway (i.e., Rasopathy genes) (Aoki *et al.*, 2008) were included in the 108 genes set. A biotinylated RNA capture library was designed using the eArray system (Agilent Technologies) according to the manufacturer's protocol. The captured DNA was subjected to a 150-bp paired-end read sequencing on the MiSeq system (Illumina).

Bioinformatics pipeline

The sequence reads from the sequencer were exported as FASTQ format files and were analyzed using sets of open-source programs by means of the default parameters; the sequence reads were aligned to the human reference genome DNA sequence (hs37d5 assembly) using the Burrows–Wheeler Alignment (BWA) tool version 0.6.1 (Li and Durbin, 2009). The Genome Analysis Toolkit (GATK) package (McKenna *et al.*, 2010) was used to perform local realignment, base quality score recalibration, and SNP/indel calls. The called SNPs/indels were annotated using snpEff version 3.1 (Cingolani *et al.*, 2012), regarded as nonpathogenic, and excluded from further analysis when they were observed in the 1000 Genomes Project (www.1000genomes.org/) or in the Japanese SNP dataset of 1208 normal individuals (Japanese Genetic Variation Consortium, 2013). The variants and alignments were visually inspected using the Integrative Genomics Viewer version 2.1 (Thorvaldsdóttir *et al.*, 2013) and VarSifter version 1.5 (Teer *et al.*, 2012). Variants in the RAS pathway, including *PTPN11*, *KRAS*, *SOS1*, *RAF1*, *SHOC2*, *HRAS*, *BRAF*, *MAPK1*, *MAP2K1*, *MAP2K2*, *MAPK3*, *SPRED1*, and *RASA1*, were evaluated for pathogenicity. Other genes were not subject to further variant analysis to avoid potential issues with incidental findings. A statistical coverage analysis was performed as described below.

Coverage analysis

Information about enrichment performance and target coverage was obtained using the software NGSrich version 0.7.8 (Frommolt *et al.*, 2012). The following parameters were measured: information about the number of reads, mean coverage, fraction of the target region with a particular depth across the 109 genes, information on the number of genes that are poorly covered, and a summary table with exon-specific coverage information at the *NF1* locus.

Direct capillary sequencing for validation

When the next-generation sequencing protocol identified truncating mutations, including nonsense mutations, frameshift mutations, and mutations at the canonical splice sites, or missense mutations that had been previously reported as being pathogenic in the literature, the variants were validated with direct capillary sequencing. In the remaining samples, all the exons were analyzed using direct capillary sequencing (Richards *et al.*, 2008). For direct capillary sequencing, 56 pairs of polymerase chain reaction (PCR) primers were designed on flanking intronic and untranslated regions to encompass the coding regions of the 58 *NF1* exons and at least 30 bp of the intronic sequence surrounding each exon (Table 2). Three primers were designed newly using primer design software, Primer3 (Rozen and Skaletsky, 2000), and the remaining primers were described elsewhere (Purandare *et al.*,

TABLE 1. LIST OF THE 109 GENES

<i>Gene</i>	<i>Chromosome</i>	<i>Basepair position (GRCh37)</i>	<i>Disease</i>	<i>Gene</i>	<i>Chromosome</i>	<i>Basepair position (GRCh37)</i>	<i>Disease</i>
<i>ACTA2</i>	10	90,694,830–90,751,146	Multisystemic smooth muscle dysfunction syndrome	<i>MSX1</i>	4	4,861,391–4,865,662	Witkop syndrome
<i>ACTC1</i>	15	35,080,296–35,087,926	Atrial septal defect	<i>MYH7</i>	14	23,881,946–23,904,869	Scapuloperoneal syndrome, myopathic type
<i>ACVRL1</i>	12	52,300,656–52,317,144	Hereditary hemorrhagic telangiectasia	<i>MYH9</i>	22	36,677,322–36,784,106	Fechtner syndrome
<i>BRAF</i>	7	140,415,748–140,624,563	Cardiofaciocutaneous syndrome	<i>NFI</i>	17	29,421,944–29,704,694	Neurofibromatosis type 1
<i>CBL</i>	11	119,076,985–119,178,858	Noonan syndrome-like disorder	<i>NIPBL</i>	5	36,876,860–37,065,925	Cornelia de Lange syndrome
<i>CDKL5</i>	X	18,443,724–18,671,748	Angelman syndrome-like disorder	<i>NOTCH2</i>	1	120,454,175–120,639,879	Alagille syndrome
<i>CHD7</i>	8	61,591,320–61,780,586	CHARGE syndrome	<i>NRAS</i>	1	115,247,084–115,259,514	Noonan syndrome
<i>COL11A1</i>	1	103,342,022–103,574,051	Fibrochondrogenesis	<i>NRTN</i>	19	5,823,817–5,828,334	Hirschsprung disease
<i>COL11A2</i>	6	33,130,468–33,160,244	Stickler syndrome	<i>NSD1</i>	5	176,560,025–176,727,213	Sotos syndrome
<i>COL1A1</i>	17	48,261,456–48,279,002	Osteogenesis imperfecta	<i>OTX2</i>	14	57,267,424–57,277,193	Syndromic microphthalmia
<i>COL1A2</i>	7	94,023,872–94,060,543	Ehlers-Danlos syndrome	<i>PHOX2B</i>	4	41,746,098–41,750,986	Congenital central hypoventilation syndrome
<i>COL2A1</i>	12	48,366,747–48,398,284	Stickler syndrome	<i>PKHD1</i>	6	51,480,144–51,952,422	Polycystic kidney and hepatic disease
<i>COL3A1</i>	2	189,839,098–189,877,471	Ehlers-Danlos syndrome	<i>PLOD1</i>	1	11,994,723–12,035,598	Ehlers-Danlos syndrome
<i>COL5A1</i>	9	137,533,650–137,736,688	Ehlers-Danlos syndrome	<i>PSPN</i>	19	6,375,304–6,375,859	Hirschsprung's disease
<i>COL5A2</i>	2	189,896,640–190,044,667	Ehlers-Danlos syndrome	<i>PITCHI</i>	9	98,205,263–98,279,246	Basal cell nevus syndrome
<i>COL9A1</i>	6	70,925,742–71,012,785	Stickler syndrome	<i>PTPN11</i>	12	112,856,535–112,947,716	LEOPARD syndrome
<i>COL9A2</i>	1	40,766,161–40,782,938	Stickler syndrome	<i>RAD21</i>	8	117,858,172–117,887,104	Cornelia de Lange syndrome
<i>COMP</i>	19	18,893,582–18,902,113	Epiphyseal dysplasia	<i>RAF1</i>	3	12,625,099–12,705,699	LEOPARD syndrome
<i>CREBBP</i>	16	3,775,054–3,930,120	Rubinstein-Taybi syndrome	<i>RASA1</i>	5	86,564,069–86,687,742	Parkes Weber syndrome
<i>CUL7</i>	6	43,005,354–43,021,682	3-M syndrome	<i>RET</i>	10	43,572,516–43,625,798	MENII
<i>DCC</i>	18	49,866,541–51,062,272	Mirror movements	<i>RUNX2</i>	6	45,296,053–45,518,818	Cleidocranial dysplasia
<i>DDX3X</i>	X	41,192,560–41,209,526	Medulloblastoma	<i>SALL1</i>	16	51,169,885–51,185,182	Townes-Brooks syndrome
<i>ECE1</i>	1	21,543,739–21,672,033	Hirschsprung disease	<i>SALL4</i>	20	50,400,550–50,419,058	Duane-radial ray syndrome
<i>EDN3</i>	20	57,875,498–57,901,046	Central hypoventilation syndrome	<i>SCN1B</i>	19	35,521,554–35,531,352	Brugada syndrome
<i>EDNRB</i>	13	78,469,615–78,549,663	Waardenburg syndrome	<i>SHH</i>	7	155,595,557–155,604,966	Holoprosencephaly
<i>EFNB1</i>	X	68,048,839–68,062,006	Craniofrontonasal dysplasia	<i>SHOC2</i>	10	112,679,300–112,773,424	Noonan-like syndrome
<i>ENG</i>	9	130,577,290–130,617,051	Hereditary hemorrhagic telangiectasia	<i>SIX3</i>	2	45,169,036–45,173,215	Holoprosencephaly

(continued)

TABLE 1. (CONTINUED)

<i>Gene</i>	<i>Chromosome</i>	<i>Basepair position (GRCh37)</i>	<i>Disease</i>	<i>Gene</i>	<i>Chromosome</i>	<i>Basepair position (GRCh37)</i>	<i>Disease</i>
<i>EP300</i>	22	41,488,613–41,576,080	Rubinstein-Taybi syndrome	<i>SIX6</i>	14	60,975,937–60,978,524	Microphthalmia with cataract
<i>FBN1</i>	15	48,700,502–48,937,984	Acromicric dysplasia	<i>SMC1A</i>	X	53,401,069–53,449,676	Cornelia de Lange syndrome
<i>FBN2</i>	5	127,593,600–127,873,734	Congenital contractual arachnodactyly	<i>SMC3</i>	10	112,327,448–112,364,391	Cornelia de Lange syndrome
<i>FGFR1</i>	8	38,268,655–38,326,351	Hypogonadotropic hypogonadism	<i>SOS1</i>	2	39,208,689–39,347,685	Noonan syndrome
<i>FGFR2</i>	10	123,237,843–123,357,971	Antley-Bixler syndrome	<i>SOX10</i>	22	38,368,318–38,380,555	PCWH syndrome
<i>FGFR3</i>	4	1,795,038–1,810,598	Achondroplasia	<i>SOX2</i>	3	181,429,711–181,432,223	Syndromic microphthalmia
<i>GDNF</i>	5	37,812,778–37,839,781	Central hypoventilation syndrome	<i>SPRED1</i>	15	38,544,924–38,649,449	Legius syndrome
<i>GFRA1</i>	10	117,816,435–118,033,125	Hirschsprung's disease	<i>SPRY2</i>	13	80,910,110–80,915,085	Holoprosencephaly
<i>GFRA2</i>	8	21,549,529–21,672,391	Hirschsprung's disease	<i>STAG1</i>	3	136,055,077–136,471,220	Cornelia de Lange syndrome
<i>GLA</i>	X	100,652,778–100,663,000	Fabry disease	<i>TAZ</i>	X	153,639,876–153,650,064	Barth syndrome
<i>HRAS</i>	11	532,241–535,560	Costello syndrome	<i>TBX22</i>	X	79,270,254–79,287,267	Abruzzo-Erickson syndrome
<i>IHH</i>	2	219,919,141–219,925,237	Acrocapitofemoral dysplasia	<i>TBX5</i>	12	114,791,734–114,846,246	Holt-Oram syndrome
<i>IRF6</i>	1	209,958,967–209,979,519	Van der Woude syndrome	<i>TCF4</i>	18	52,889,561–53,303,251	Pitt-Hopkins syndrome
<i>JAG1</i>	20	10,618,331–10,654,693	Alagille syndrome	<i>TCOF1</i>	5	149,737,201–149,779,870	Treacher Collins syndrome
<i>KCNE1</i>	21	35,790,909–35,884,572	Jervell and Lange-Nielsen syndrome	<i>TGFBR1</i>	9	101,867,411–101,916,473	Loeys-Dietz syndrome
<i>KCNJ2</i>	17	68,164,756–68,176,188	Andersen syndrome	<i>TGFBR2</i>	3	30,647,993–30,735,633	Loeys-Dietz syndrome
<i>KCNQ1</i>	11	2,466,220–2,870,339	Jervell and Lange-Nielsen syndrome	<i>TGIF1</i>	18	3,411,924–3,458,408	Holoprosencephaly
<i>KIF1A</i>	10	70,748,476–70,776,738	Goldberg-Shprintzen megacolon syndrome	<i>TP63</i>	3	189,348,941–189,615,067	EEC syndrome
<i>KIF26A</i>	14	104,605,059–104,647,234	Megacolon	<i>TRAPPC10</i>	21	45,432,205–45,526,432	Holoprosencephaly
<i>KRAS</i>	12	25,358,179–25,403,869	Noonan syndrome	<i>TRIM37</i>	17	57,059,998–57,184,265	Mulibrey nanism
<i>L1CAM</i>	X	153,126,968–153,151,627	CRASH syndrome	<i>TSC1</i>	9	135,766,734–135,820,093	Tuberous sclerosis
<i>LAMP2</i>	X	119,560,002–119,603,203	Danon disease	<i>TSC2</i>	16	2,097,471–2,138,712	Tuberous sclerosis
<i>MAP2K1</i>	15	66,679,181–66,783,881	Cardiofaciocutaneous syndrome	<i>TWIST1</i>	7	19,039,314–19,157,294	Saethre Chotzen syndrome
<i>MAP2K2</i>	19	4,090,318–4,124,125	Cardiofaciocutaneous syndrome	<i>VHL</i>	3	10,183,318–10,195,353	Von Hippel-Lindau syndrome
<i>MAPK1</i>	22	22,113,945–22,221,969	Acromesomelic dysplasia	<i>VSX2</i>	14	74,706,174–74,729,440	Microphthalmia
<i>MAPK3</i>	16	30,125,425–30,134,629	Cardiac hypertrophy	<i>ZEB2</i>	2	145,141,941–145,277,957	Mowat-Wilson syndrome
<i>MECP2</i>	X	153,287,024–153,363,187	Rett syndrome	<i>ZIC2</i>	13	100,634,025–100,639,018	Holoprosencephaly
<i>MIDI</i>	X	10,413,349–10,851,828	Opitz GBBB syndrome				

TABLE 2. LIST OF POLYMERASE CHAIN REACTION PRIMERS

Exon	Primer sequence (5'-3')	Amplicon size	Reference	Exon	Primer sequence (5'-3')	Amplicon size	Reference
1	CAGACCCCTCTCCTTGCCCTCTT GGATGGAGGGTCGGAGGCTG	439	Purandare <i>et al.</i> (1995)	29	ATATGGAGCAGGTATAATAAAC AAACACAGCGGTCTATGTG	181	Bausch <i>et al.</i> (2007)
2	CGTCATGATTTTCAATGGCAAG GCTCACTGAATCTAAACCCAGC	438	Bausch <i>et al.</i> (2007)	30	CGTTGCACCTGGCTTAATGTCTG CCATCAGCAGCTAGATCCTTCTTT	327	Bausch <i>et al.</i> (2007)
3	TTTCACCTTTTCAGATGTGTGTG TGGTCCACATCTGTACTTTG	245	Purandare <i>et al.</i> (1995)	31	TTTTCTGIGATTTCATAGCC GATATTCTTAAACAACACAGCA	400	This report
4	TTAAATCTAGGTGGTGTGT AAACTCATTTCTCTGGAG	517	Han <i>et al.</i> (2001)	32	CTTATACTCAATTCTCAACTCC GAATTTAAGATAGCTAGATTATC	226	Bausch <i>et al.</i> (2007)
5	GAGATACCACACCTGTCCCCTAA TTGACCCAGTGTATTTTTCAGA	215	Bausch <i>et al.</i> (2007)	33	GACITTCATACAAATAATATCTG TATTTGATTCAAAACAGAGCAAC	195	Bausch <i>et al.</i> (2007)
6	TTTCCTAGCAGACAACTATCGA AGGATGCTAACACACAGCAAT	308	Han <i>et al.</i> (2001)	34	CTCCATATTGTAACTCTTAGTTA GGAGAGTGTTCACATATCCC	298	Bausch <i>et al.</i> (2007)
7	GAAGGAAGTTAGAAGTTTGTG CACAAGTAGGCATTTAAAAAGA	211	Bausch <i>et al.</i> (2007)	35	GTTACAAGTTAAAGAAATGTGTAG CTAACAAAGTGGCCTGTGGCAAAAC	298	Purandare <i>et al.</i> (1995)
8	CATGTTATCTTTTAAAAATGTTGCC ATAATGGAAATAATTTTGCCCTCC	301	Han <i>et al.</i> (2001)	36	TTTATTGTTTATCCAAATTATAGACTT TCCTGTTAAGTCAACTGGGAAAAAAC	296	Purandare <i>et al.</i> (1995)
9	CTGTAAATTGCTATAAATATTAGC CATAATACATTATGCTAGAAAATTC	328	Bausch <i>et al.</i> (2007)	37	TGAATCCAGACTTTTGAAGAATTGTT CTAGGGAGGCCAGGATATAGTCTAGT	644	Bausch <i>et al.</i> (2007)
10	GTAATGTGTGTGATGTTATTACATG GTCTTTTGTGTTTATAAAGGATAACA	273	Bausch <i>et al.</i> (2007)	38	GGTTGGTTTCTGGAGCCTTTTAGA CAACAAACCCCAAAATCAAACTGA	467	Bausch <i>et al.</i> (2007)
11	CTTCTATTGCTGTTCTTTTGG CCTTTTGAAACCAAGAGTGCA	264	Bausch <i>et al.</i> (2007)	39	TTGGAACATATAAGGAAAAATACGTTT AGGGTTTCTTTGAATTCTCTTAGA	321	Bausch <i>et al.</i> (2007)
12	ACGTAATTTTGTACTTTTCTTTC CAATAGAAAGGAGGTGAGATTTC	222	Purandare <i>et al.</i> (1995)	40	ATAATTGTTGATGTGATTTTCATTG AATTTTGAAACCAGATGAAGAG	424	Han <i>et al.</i> (2001)
13	GCAAAAACGATTTTCATTGTTTGT GCGTTTCAGCTAAACCCCAATT	403	This report	41	TTGATTAGGCTGTTCCTCAATGAA CAAAACAATAAACCTCTCTGATGAT	298	Bausch <i>et al.</i> (2007)
14	ATTGAAGTTTCTTTTTCCTTG GTATAGACATAAACATACCATTC	275	Bausch <i>et al.</i> (2007)	42	GTGCTAAAACCTTTGAGTCCCATGT ATAATCTATATTGATCAGGTGAAGTA	415	Bausch <i>et al.</i> (2007)
15	CCAAAATGTTTGAGTGAGTCT ACCATAAAACCTTTGGAAGTG	256	Han <i>et al.</i> (2001)	43	GCAAGGAGCATTAATAACAATGTATC CCATGCAAGTGTTTATTTAAGC	507	Bausch <i>et al.</i> (2007)

(continued)

TABLE 2. (CONTINUED)

Exon	Primer sequence (5'-3')	Amplicon size	Reference	Exon	Primer sequence (5'-3')	Amplicon size	Reference
16	AAACCTTACAAGAAAACTAAGCT ATTACCATTCCAAATATCTTCCA	303	Purandare <i>et al.</i> (1995)	44-45	GGTAACAGGTCACCTTAATGACATCA GACCTCAAAATTTAAACGTCTTTTAGA	512	Bausch <i>et al.</i> (2007)
17	CTCTGGTTGTCAAGTGCTTC CAGAAAACAACAGAGCACAT	261	Han <i>et al.</i> (2001)	46	CATTCGAGATTTCAGTTTAGGAG AAGTAACATTCACACATGATACCC	236	Abernathy <i>et al.</i> (1997)
18	CCCAAGTTGCAAAATATATGTC GTGCTTTGAGGCAGACTGAG	336	Bausch <i>et al.</i> (2007)	47	TCCCCAAAAGAGAAAACATGG AGCAACAAGAAAAAGATGGAAGAGT	334	Bausch <i>et al.</i> (2007)
19	TGAAGCATTTGCTCTGCTCT GTTTCAAACTTGATGTATATTA	347	Bausch <i>et al.</i> (2007)	48	CTACTGTGTGAACCTCATCAACC GTAAGACATTAAGGGCTAACTTACTTC	284	Abernathy <i>et al.</i> (1997)
20	ACTTGCTGTAGCTGATTGA ACTTTACTGAGCGACTCTTGAA	247	Han <i>et al.</i> (2001)	49	TCAGGGAAGAAAGACCTCAGCAGATGC TGAACCTTTCTGCTCTGCCACGCAACC	328	Abernathy <i>et al.</i> (1997)
21	GGAAGAAATGTTGGATAAAGCA AAACAAGTCACTCTATTCATAGA	579	Bausch <i>et al.</i> (2007)	50	GTGCACATTTAACAGGTACTAT CTTCCTAGGCCATCTCTAGAT	373	Han <i>et al.</i> (2001)
22	TATCTGTATGCTTATTTGGCTCTA GTGCAGTAAAGAAATGGCCAG	385	Bausch <i>et al.</i> (2007)	51	CTTGGAAGGAGCAAAACGATGGTTG CAAAAACCTTTGCTACACTGACATGG	356	Abernathy <i>et al.</i> (1997)
23	AGAAGTTGTACGTTCTTTTCT CTCCTTTCTACCAATAACCGC	367	Purandare <i>et al.</i> (1995)	52	GTCCAGGGATGTATTAGAGCTTT TGACTTTTCATGTACTCTCCCACTT	325	Bausch <i>et al.</i> (2007)
24	TGTTCCTTCTGGCTTTTAT ATCTCAAAGTTTAAATACACA	365	This report	53-54	TGAAGTGATTATCCAGGTGTTGA AAAGACAGGCACGAGGTGA	506	Bausch <i>et al.</i> (2007)
25	TGAGGGGAAGTGAAAGAACT GGCTTTATTTGCTTTTGGCT	235	Han <i>et al.</i> (2001)	55	AATTTTGGCACATTTATCTGGG AGCAAGTTTCATCAACCATCCTT	290	Bausch <i>et al.</i> (2007)
26	CCACCTGGGTGATTATCG TAATTTTGTCTCTTACATGC	402	Purandare <i>et al.</i> (1995)	56	CTGTTACAATTAAAGATACCTTGC TGTGTCTTCTTAAAGCAGGCATAC	185	Abernathy <i>et al.</i> (1997)
27	TGGTCTCATGCATCCATA CATCTTTCTTGGCTCTGA	474	Han <i>et al.</i> (2001)	57	TTTGTGCTTCAGATGGGATTTAC AAGGGAATTCCTAATGTGTGTGTC	351	Abernathy <i>et al.</i> (1997)
28	TGCTACTCTTTAGCTTCCTAC CCTTAAAGAAGACAATCAGCC	331	Purandare <i>et al.</i> (1995)	58	AAGCGACACATGACTGCAATG TGGCTTTCATCACTGGCCA	571	Bausch <i>et al.</i> (2007)

1995; Abernathy *et al.*, 1997; Han *et al.*, 2001; Bausch *et al.*, 2007). The 3' end of the primers were designed so as not to match the genomic sequences of any of the highly homologous pseudogene sequences to avoid mispriming to the pseudogenes. Direct capillary sequencing was performed using the ABI BigDye version 1.1 Terminator Cycle Kit (Life Technologies) and the ABI Prism 3500 Capillary Array Sequencer (Life Technologies). The sequence data were analyzed using Mutation Surveyor version 4.0.6 (Softgenetics) and Sequencher version 5.0 (Gene Codes Corp.).

Multiplex ligation-dependent probe amplification

When the next-generation sequencing protocol did not identify truncating mutations, canonical splice-site mutations, or other point mutations previously reported as pathological missense change or splicing defect, the remaining samples were screened for single/multiple exon deletions or duplications using a multiplex ligation-dependent probe amplification method (De Luca *et al.*, 2007) (SALSA P081/082-B2 NF1 MLPA assay kit; MRC-Holland) concurrently with the direct capillary sequencing of all the exons, as stated above.

Analysis algorithm of the variants

Missense variants that have not been reported as pathogenic in the literature and were not observed in the 1208 normal Japanese exome data were evaluated for potential pathogenicity using five bioinformatics programs, including SIFT (Kumar *et al.*, 2009), Polyphen2 (Adzhubei *et al.*, 2010), LRT (Chun and Fay, 2009), MutationTaster (Schwarz *et al.*, 2010), and PhyloP (Siepel *et al.*, 2009). When four of the five programs predicted the results as pathogenic ("damaging" with SIFT, "probably damaging" with PolyPhen2, "deleterious" with LRT, "disease causing" with MutationTaster, or "conserved" with PhyloP), we interpreted the clinical significance of the missense mutation as being putatively pathogenic.

Results

Performance of sequence capturing

In the custom-designed mutation analysis panel for the screening of classic genetic syndromes, the number of bases for targeted capturing was 459,952 bp over 1888 regions of the 109 target genes, including *NF1*. An average of 207,203 reads per sample were mapped and aligned uniquely to the targeted bases of the 109 genes among the 86 samples.

As far as the *NF1* locus was concerned, all the exons were highly covered with a coverage of 190.7x per sample. Overall, 99.3% of the regions were covered at least with a coverage of 5x and 98.8% of the regions were covered at least with a coverage of 30x. The mean coverage of all the exons in the 86 samples indicated that all the exons, but exon 1, were appropriate for base calling by next-generation sequencing (Table 3). Because of the poor coverage, exon 1 was sequenced using the direct capillary sequencing in all 86 samples, none of which had any variants.

The mean coverage over the entire targeted regions per sample was 131.0x, and most of the regions were well covered (Table 4). Overall, 97.1% of the regions were covered at least 5x coverage, and 84.4% of the regions were covered at

TABLE 3. MEAN COVERAGE OF *NF1* EXONS AMONG 86 PATIENTS

Exon	Coverage (x)	Exon	Coverage (x)
1	1.7	30	239.7
2	220.2	31	175.9
3	168.8	32	157.0
4	169.5	33	124.6
5	145.0	34	216.0
6	170.9	35	152.1
7	164.8	36	189.3
8	144.0	37	284.7
9	182.7	38	261.5
10	174.1	39	230.9
11	179.2	40	217.3
12	194.9	41	206.8
13	120.0	42	276.9
14	141.2	43	195.7
15	86.9	44	181.1
16	152.7	45	166.3
17	212.6	46	156.4
18	251.3	47	185.7
19	127.1	48	159.4
20	215.4	49	241.5
21	175.2	50	79.1
22	191.4	51	174.3
23	103.1	52	238.4
24	194.0	53	235.9
25	96.6	54	217.5
26	212.1	55	136.8
27	209.6	56	320.0
28	238.7	57	220.5
29	208.5	58	122.6

least 30x coverage. Some exons of *NF1* and other regions were less well covered than others. Exon 15 and exon 50 of *NF1*, together with the *COMP* gene and the *PHOX2B* gene, had relatively low coverages of 86.9x, 79.1x, 55.3x, and 19.2x, respectively.

NF1 has seven highly homologous pseudogene sequences located in chromosomes other than chromosome 17 (2q12-q13, 12q11, 14p11-q11, 15q11.2, 18p11.2, 21p11-q11, and 22p11-q11), on which *NF1* resides (Upadhyaya, 2008). We scrutinized the mapped reads among 10 arbitrarily selected patients; all the pseudogene sequences were mapped to their orthologous locations in the genome rather than the *NF1* locus on chromosome 17.

Coverage of the 108 genes other than the *NF1* gene was evaluated in all 86 samples. The mean coverage of all 108 genes on the same diagnostic panel indicated that the mean coverage ranged from 19.2x to 254.1x, with mean of 114.5x (Table 4).

Mutation detection

The next-generation sequencing protocol described above led to the identification of pathological *NF1* mutations in 70 of the 86 patients who met the NIH diagnostic criteria. The clinical information is listed in Table 5. All the 70 patients harbored mutations in a heterozygous state: 30 nonsense mutations, 19 frameshift mutations, 8 canonical splice-site mutations, and 6 point mutations that were previously reported and have been shown to lead to aberrant splicing

TABLE 4. SUMMARY OF THE COVERAGE OF 109 GENES

<i>Gene</i>	<i>Coverage (x)</i>	<i>Gene</i>	<i>Coverage (x)</i>
<i>ACTA2</i>	103.7	<i>MSX1</i>	49.4
<i>ACTC1</i>	111.4	<i>MYH7</i>	103.5
<i>ACVRL1</i>	60.4	<i>MYH9</i>	97.5
<i>BRAF</i>	160.0	<i>NF1</i>	190.7
<i>CBL</i>	192.3	<i>NIPBL</i>	175.9
<i>CDKL5</i>	146.1	<i>NOTCH2</i>	153.4
<i>CHD7</i>	150.6	<i>NRAS</i>	254.1
<i>COL11A1</i>	160.5	<i>NRTN</i>	45.8
<i>COL11A2</i>	66.8	<i>NSD1</i>	160.1
<i>COL1A1</i>	47.2	<i>OTX2</i>	115.1
<i>COL1A2</i>	127.0	<i>PHOX2B</i>	19.2
<i>COL2A1</i>	76.2	<i>PKHD1</i>	173.6
<i>COL3A1</i>	123.1	<i>PLOD1</i>	68.3
<i>COL5A1</i>	52.0	<i>PSPN</i>	66.5
<i>COL5A2</i>	159.2	<i>PTCH1</i>	111.0
<i>COL9A1</i>	147.4	<i>PTPN11</i>	152.6
<i>COL9A2</i>	52.4	<i>RAD21</i>	198.5
<i>COMP</i>	55.3	<i>RAF1</i>	154.9
<i>CREBBP</i>	50.1	<i>RASA1</i>	171.7
<i>CUL7</i>	68.8	<i>RET</i>	97.4
<i>DCC</i>	188.4	<i>RUNX2</i>	144.5
<i>DDX3X</i>	118.1	<i>SALL1</i>	91.7
<i>ECE1</i>	80.6	<i>SALL4</i>	93.8
<i>EDN3</i>	64.6	<i>SCN1B</i>	69.3
<i>EDNRB</i>	178.9	<i>SHH</i>	50.3
<i>EFNB1</i>	47.8	<i>SHOC2</i>	195.5
<i>ENG</i>	36.4	<i>SIX3</i>	80.0
<i>EP300</i>	191.0	<i>SIX6</i>	67.6
<i>FBN1</i>	177.2	<i>SMC1A</i>	134.7
<i>FBN2</i>	171.0	<i>SMC3</i>	157.2
<i>FGFR1</i>	102.7	<i>SOS1</i>	180.5
<i>FGFR2</i>	157.5	<i>SOX10</i>	45.1
<i>FGFR3</i>	34.8	<i>SOX2-OT</i>	89.0
<i>GDNF</i>	200.5	<i>SPRED1</i>	137.0
<i>GFRA1</i>	103.1	<i>SPRY2</i>	141.7
<i>GFRA2</i>	49.9	<i>STAG1</i>	193.3
<i>GLA</i>	121.1	<i>TAZ</i>	45.1
<i>HRAS</i>	44.4	<i>TBX22</i>	117.7
<i>IHH</i>	73.4	<i>TBX5</i>	124.2
<i>IRF6</i>	128.5	<i>TCF4</i>	170.8
<i>JAG1</i>	147.5	<i>TCOF1</i>	68.4
<i>KCNE1</i>	88.4	<i>TGFBR1</i>	190.0
<i>KCNJ2</i>	226.4	<i>TGFBR2</i>	89.6
<i>KCNQ1</i>	80.5	<i>TGIF1</i>	77.1
<i>KIAA1279</i>	186.5	<i>TP63</i>	182.5
<i>KIF26A</i>	33.7	<i>TRAPPC10</i>	139.7
<i>KRAS</i>	214.4	<i>TRIM37</i>	85.4
<i>L1CAM</i>	42.7	<i>TSC1</i>	157.8
<i>LAMP2</i>	128.2	<i>TSC2</i>	49.4
<i>MAP2K1</i>	151.4	<i>TWIST1</i>	47.9
<i>MAP2K2</i>	35.6	<i>VHL</i>	84.5
<i>MAPK1</i>	168.5	<i>VSX2</i>	29.7
<i>MAPK3</i>	87.1	<i>ZEB2</i>	218.9
<i>MECP2</i>	80.4	<i>ZIC2</i>	72.9
<i>MIDI</i>	126.4		

according to reverse transcription (RT)-PCR studies, together with seven nonsynonymous substitutions (Table 5). Among the seven nonsynonymous substitutions, four were previously reported to be pathogenic based on functional assays or the inheritance pattern within the families (Li *et al.*, 1992; Fahsold *et al.*, 2000; Lee *et al.*, 2006).

Three samples with missense mutations that have never been reported in the literature were predicted to be pathogenic based on the consensus predication from multiple bioinformatics programs. Five programs, including SIFT, Polyphen2, LRT, Mutation Taster, and PhyloP, predicted potential pathogenicity as follows: c.2183T>G (p.Val728Gly) mutation was predicted to be pathogenic by all five programs, and c.2540T>G (p.Leu847Arg) and c.6818A>T (p.Lys2273Met) mutations were predicted to be pathogenic by four of the five bioinformatics programs. None of the three missense mutations resided within the critical functional domain, GAP-related domain that regulates the RasGAP activity.

Comparison of the distributions of nonsense, splice-site variants, and missense mutations in the Japanese population versus the northern European population, as reported by Messiaen *et al.* (2000), Nemethova *et al.* (2013), Sabbagh *et al.* (2013), and Valero *et al.* (2011), revealed no statistically significant differences among the groups ($p=0.203$ using the Fisher exact test for countable data).

Together with these 3 samples, which were subject to bioinformatics programs, 16 samples without truncating mutations or missense mutations, previously reported to be pathogenic, were further sequenced using direct capillary sequencing methods. All the exons were sequenced, including exon 1, and no additional point mutations or small indels were detected. These 19 patients were further screened for relatively large deletions that would span an entire exon or multiple exons and thus escape from direct capillary sequencing. Among 10 patients, 5 were shown to have a whole *NF1* deletion, 2 had multiple-exon deletions, and 3 had single-exon deletions. These five patients with a whole *NF1* deletion were apparently homozygous for all the SNPs for the entire *NF1* region according to the next-generation sequencing analysis.

Overall, no appreciable genotype-phenotype correlation was detected in the present study (Table 5). Variants were detected in genes other than *NF1* when the same criteria used in the *NF1* analysis were applied to these genes (Table 5). None of these variants was classified as truncating mutations and none of them listed in the Human Genome Mutation Database (HGMD) (Cooper *et al.*, 1998). Such rare variants of unknown significance among the genes on the panel were found in at least two-thirds of the patients. Patients with variants in genes other than *NF1* did not necessarily exhibit a severe *NF1* phenotype.

Discussion

The present study demonstrated that next-generation sequencing with in-solution hybridization-based enrichment provides a high mutation detection rate comparable to that of conventional direct capillary sequencing methods for the molecular diagnosis of neurofibromatosis. The overall mutation detection rate using the currently reported method in 86 patients who met the clinical diagnostic criteria was 81.4% (70/86). Among the 16 samples in which mutations were not detected using next-generation sequencing, 10 samples were later shown to have large deletions using a different method, multiplex ligation-dependent probe amplification (MLPA). Because of their large sizes, the 10 large deletions would not have been detected using the direct capillary sequencing

TABLE 5. SUMMARY OF PATHOGENIC MUTATIONS DETECTED BY NEXT-GENERATION SEQUENCING

Exon	Genomic mutation	Amino acid substitution	Type of mutation	Reference	Age	Familial	Symptoms	Variations of unknown significance in rasopathy genes	Number of mutations in other genes
2	c.83_84insG	p.Asn29Glufs*9	Frameshift		68	Yes	P,N	RASA1 c.293C>T p.Ala98Val	2
3	c.264_265insA	p.Thr89Asnfs*18	Frameshift		44	Yes	P,B,N		1
5	c.491T>A	p.Leu164*	Nonsense		50	Yes	P,B,O,N		1
5	c.495-498delTGTT	p.Cys167Glnfs*10	Frameshift		41	No	P,N,L		1
5	c.499_500insG	p.Cys167Trpfs*7	Frameshift		27	No	P,B,N,L		1
5	c.574C>T	p.Arg192*	Nonsense		32	No	P,N,L		2
10	c.1105C>T	p.Gln369*	Nonsense		40	Yes	P,N,L		1
11	c.1241T>G	p.Leu414Arg	Missense ^a	Lee <i>et al.</i> (2006)	21	No	P,N,L		1
11	c.1246C>T	p.Arg416*	Nonsense		32	Yes	P,B,N		1
12	c.1381C>T	p.Arg461*	Nonsense		3	No	P	RASA1 c.669G>C p.Gln223His	1
12	c.1381C>T	p.Arg461*	Nonsense		67	Yes	P,B,N		1
12	c.1381C>T	p.Arg461*	Nonsense		41	Yes	P,B,N		0
13	c.1466A>G	p.Tyr489Cys	Missense ^a	Messiaen <i>et al.</i> (2000)	36	No	P,N		1
13	c.1466A>G	p.Tyr489Cys	Missense ^a	Messiaen <i>et al.</i> (2000)	63	Yes	P,B,N		0
13	c.1466A>G	p.Tyr489Cys	Missense ^a	Messiaen <i>et al.</i> (2000)	71	No	P,N,L		1
13	c.1527+1_+4delGTAA	p.Gln514Argfs*43	Splicing Frameshift		30	No	P,N,L		2
14	c.1541_1542delAG		Splicing		52	No	P,B,N		1
15	c.1721+3A>G			Purandare <i>et al.</i> (1994)	40	Yes	P,B,N		0
16	c.1726C>T	p.Gln576*	Nonsense		36	No	P,N		0
16	c.1754_1757delACTA	p.Thr586Valfs*18	Frameshift		49	Yes	P,N		0
16	c.1765C<T	p.Gln589*	Nonsense		40	No	P,N		1
16	c.1832delT	p.Asn614Ilefs*17	Frameshift		80	No	P,N,L		3
17	c.1876_1877insT	p.Tyr628Leufs*6	Frameshift		79	Yes	P,B,N,L		2
17	c.1885G>A	p.Gly629Arg	Missense ^a	Gasparini <i>et al.</i> (1996)	57	Yes	P,N		2
18	c.2041C>T	p.Arg681*	Nonsense		23	No	P,N		1
18	c.2041C>T	p.Arg681*	Nonsense		35	Yes	P,B,N		1
18	c.2087G>A	p.Trp696*	Nonsense		58	Yes	P,B,N,L		0
18 ^b	c.2183T>G	p.Val728Gly	Missense		67	Yes	P,N		0
21	c.2423delT	p.His809Thrfs*12	Frameshift		43	Yes	P,N		1
21	c.2540T>C	p.Leu847Pro	Missense ^a	Fahsold <i>et al.</i> (2000)	33	Yes	P,N,L		0
21	c.2540T>C	p.Leu847Pro	Missense ^a	Fahsold <i>et al.</i> (2000)	59	Yes	P,B,N,L		0

(continued)

TABLE 5. (CONTINUED)

Exon	Genomic mutation	Amino acid substitution	Type of mutation	Reference	Age	Familial	Symptoms	Variations of unknown significance in rasopathy genes	Number of mutations in other genes
21 ^b	c.2540T>G	p.Leu847Arg	Missense		55	No	P,N		0
21	c.2446C>T	p.Arg816*	Nonsense		52	Yes	P,N,L		0
22	c.2851-5_-2delTTTA		Splicing		19	No	P,B,N,L		1
23	c.3048T>A	p.Cys1016*	Nonsense		50	Yes	P,B,N		0
24	c.3132C>A	p.Tyr1044*	Nonsense		12	Yes	P,O,N		0
25	c.3213_3214delAA	p.Ser1072Hisfs*16	Frameshift		29	No	P,N,L		2
27	c.3595_3596insGG	p.Thr1199Argfs*17	Frameshift		20	No	P,N,L		1
27	c.3615_3616delITG	p.Phe1205Leufs*12	Frameshift		37	Yes	P,B,N		2
27	c.3615_3616delITG	p.Phe1205Leufs*12	Frameshift		64	Yes	P,B,N,L		1
28	c.3709-2A>G		Splicing		44	No	P,B,N,L		0
28	c.3765_3766insCT	p.Leu1257Cysfs*10	Frameshift		29	No	P,B,N,L		2
28	c.3826C>T	p.Arg1276*	Nonsense		21	No	P,O,B,N,L		0
29	c.3888T>A	p.Tyr1296*	Nonsense		49	No	P,N,L		0
30	c.4084C>T	p.Arg1362*	Nonsense		27	No	P,N		1
32	c.4329delA	p.Lys1444Argfs*25	Frameshift		50	Yes	P,B,N,L		0
32	c.4330A>G	p.Lys1440Glu	Missense ^a	Li <i>et al.</i> (1992)	40	No	P,N,L		0
33	c.4430+1G>A		Splicing		49	Yes	P,B,N		2
34	c.4544delA		Frameshift		35	Yes	P,N		2
35	c.4716_4724+6 delTATGACTAGGTAAAG	p.Gln1515Argfs*59	Splicing		50	No	P,B,N,L		1
36	c.4743_4744delAG	p.Glu1582Argfs*39	Frameshift		36	No	P,B,N,L		2
36	c.4769T>G	p.Leu1590*	Nonsense		45	No	P,N		1
37	c.4873_4874insA	p.Tyr1625*	Nonsense		63	No	P,B,N		1
37	c.5198T>G	p.Leu1733*	Nonsense		40	No	P,B,N,L		1
38	c.5269-6_5276 delITCCAGGTGTTTC		Splicing		38	No	P,N,L		1
38	c.5269-1G>A		Splicing		39	Yes	P,B,N,L		0
38	c.5516_5517insC	p.Glu1841Profs*21	Frameshift	Ars <i>et al.</i> (2003)	31	Yes	P,B,N		1
38	c.5609G>A	p.Arg1870Gln	Missense ^a		69	Yes	P,B,N		0
40	c.5902C>T	p.Arg1968*	Nonsense		22	No	P,N		1
44	c.6675G>A	p.Trp2225*	Nonsense		54	No	P,O,B,N		3
45	c.6772C>T	p.Arg2258*	Nonsense		69	Yes	P,N		0
45	c.6772C>T	p.Arg2258*	Nonsense		52	Yes	P,B,N,L		1
45 ^b	c.6818A>T	p.Lys2273Met	Missense		46	No	P,N		1

(continued)

TABLE 5. (CONTINUED)

Exon	Genomic mutation	Amino acid substitution	Type of mutation	Reference	Age	Familial	Symptoms	Variations of unknown significance in rasopathy genes	Number of mutations in other genes
46	c.6850_6853delACTT	p.Tyr2285Thrfs*5	Frameshift		42	Yes	P,N		1
46	c.6853_6854insA	p.Tyr2285*	Nonsense		21	No	P,N		0
46	c.6853_6854insA	p.Tyr2285*	Nonsense		28	No	P,N		0
46	c.6904C>T	p.Gln2302*	Nonsense		37	Yes	P,N,L		1
47	c.6950G>A	p.Trp2317*	Nonsense		25	No	P,B,N,L		0
50	c.7348C>T	p.Arg2450*	Nonsense		46	No	P,B,N,L		0
54	c.7970+1_+4delGTAA		Splicing		41	Yes	P,N,L		2
			ex1 to 58 deletion		13	No	P,N,L		3
			ex1 to 58 deletion		29	No	P,N		1
			ex1 to 58 deletion		68	No	P,N		1
			ex1 to 58 deletion		58	No	P,B,N,L		1
			ex1 to 58 deletion		34	No	P,B,N		1
			ex1 deletion		68	No	P,N,L		1
			ex3 to 4 deletion		59	No	P,N,L		0
			ex6 to 51 deletion		36	Yes	P,N,L		2
			ex8 deletion		28	Yes	P,N		0
			ex12 deletion		55	No	P,N		1
					37	No	P		0
					50	No	P,N		0
					45	Yes	P,N,L		2
					30	No	P,N		0
					34	Yes	P,B,N		1
					25	No	P		0

^aPreviously reported to cause aberrant splicing.^bPredicted to be pathogenic by bioinformatics programs.

Symptoms: P, pigment; O, optic nerve tumor; B, bone manifestation; N, neurofibroma; L, Lisch nodules; HGMD, Human Genome Mutation Database.

method, which is currently considered to be the gold standard. The mutation detection rate was 92.1% (70/76) when these 10 samples were excluded from the calculation of the detection rate.

Among the 10 samples with large deletions, 5 patients with a whole *NF1* deletion could have been suspected of having a whole gene deletion, in that these patients were apparently homozygous for all the SNPs for the entire *NF1* region according to the next-generation sequencing data. The remaining five patients with a partial deletion of the *NF1* gene, as documented using MLPA, would not have been reliably inferred to have such a deletion based on the relatively short runs of homozygosity.

Recent reports on comprehensive *NF1* screening using the direct capillary sequencing method revealed that the detection rate was 89.5–96.3% when cases with large deletions detectable only by using MLPA were excluded [93.4%: Valero *et al.* (2011), 89.5%: Nemethova *et al.* (2013), 96.3%: Sabbagh *et al.* (2013)]. Hence, the performance of the presently reported protocol was comparable with that of the direct capillary sequencing methods.

The present protocol uses genomic DNA as the starting material, unlike other protocols using puromycin-tested Epstein-Barr virus cell lines as the starting material for RT-PCR (Messiaen *et al.*, 2000). Apparently, the use of genomic DNA is much easier in clinical settings. Yet, genetic testing based on genomic DNA, including the previously reported protocol, cannot predict potential splicing defects caused by point mutations. The use of RNA would be more sensitive to splicing abnormalities, if any, because of the possibility of mutations located deep in the intron or aberrant splicing defects caused by point mutations within coding sequences that were not evaluated in the presently reported protocol. However, such deep intronic mutations or splicing defects may be relatively rare, given the high overall detection rate of 92.1% in the present study.

The mean coverage of the entire target regions per sample was 131.0x. This coverage figure was considered to be sufficient for the detection of heterozygous base changes. Furthermore, the observation that rare variants in some genes on the panel were found in at least two-thirds of the patients supports the notion that the diagnostic performance of the panel for other genes is as robust as it is for *NF1*. Thus, our results regarding the validity of next-generation sequencing for the molecular diagnosis of the *NF1* gene, in comparison with direct capillary sequencing, can be extrapolated to the molecular diagnosis of other classic malformation syndromes.

Nevertheless, exon-to-exon variations in the coverage figures should be carefully evaluated. The extremely low coverage of the *NF1* exon1 can be ascribed to its extremely high GC content of 77.5%, in that a GC content of 60% or higher is associated with a sharp decrease in the read depth (Chilamakuri *et al.*, 2014). Similarly, a relatively low coverage of the *COMP* gene of 55.3x may be associated with a GC content of 63.4%. Exon 15 and exon 50 of *NF1*, together with the *PHOX2B* gene, had relatively low coverages of 86.9x, 79.1x, and 19.2x, respectively. The underlying cause of such variations is currently unexplained in that the GC contents of these regions were 32.2%, 39.4%, and 54.5%, respectively.

We estimated that the cost for consumables would be about USD 400 for direct capillary sequencing of the *NF1* gene, excluding labor costs. The estimated cost for consumables for

the NGS panel analysis would be comparable. Hence, if we were to screen for the single *NF1* gene, the cost–benefit of next-generation sequencing may not be advantageous. However, if we were to screen for genes associated with conditions to be differentiated from neurofibromatosis using direct capillary sequencing, the consumable cost would be multiplied, whereas the cost for the screening of extra genes using next-generation sequencing would remain fixed. Indeed, the molecular diagnosis of Legius syndrome and Noonan syndrome would be helpful for the clinical management and outcome predictions of patients with café-au-lait spots, since patients with these conditions are unlikely to develop neurofibromas or other hamartomatous complications.

The availability of a mutation analysis panel, like the one presented herein, plays a critical role in differentiating the underlying genetic cause of patients whose diagnosis is uncertain from a clinical standpoint (Takenouchi *et al.*, 2013a, 2013b). The use of a whole-exome panel would be advantageous because of its comprehensiveness. However, apart from the higher cost of a whole-exome analysis, a panel approach enables a higher sensitivity (Chin *et al.*, 2013) because the average coverage, and thus the sensitivity, is higher using a panel approach (close to 100%) compared with a whole-exome approach (85%–95%).

Acknowledgments

All the authors would like to express their sincere appreciation to Mr. Yuji Sugie for his special support and all the patients and their families who were enrolled in this study. This work was partly supported by Research on Applying Health Technology and Research on Rare and Intractable Diseases from the Ministry of Health, Labour and Welfare, Japan.

Author Disclosure Statement

The authors declare that they have no competing interests.

References

- Abernathy CR, Rasmussen SA, Stalker HJ, *et al.* (1997) *NF1* mutation analysis using a combined heteroduplex/SSCP approach. *Hum Mutat* 9:548–554.
- Adzhubei IA, Schmidt S, Peshkin L, *et al.* (2010) A method and server for predicting damaging missense mutations. *Nat Methods* 7:248–249.
- Aoki Y, Niihori T, Narumi Y, *et al.* (2008) The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders. *Hum Mutat* 29:992–1006.
- Aramaki M, Udaka T, Torii C, *et al.* (2006) Screening for CHARGE syndrome mutations in the *CHD7* gene using denaturing high-performance liquid chromatography. *Genet Test Mol Biomarkers* 10:244–251.
- Ars E, Kruyer H, Morell M, *et al.* (2003) Recurrent mutations in the *NF1* gene are common among neurofibromatosis type 1 patients. *J Med Genet* 40:e82.
- Bausch B, Borozdin W, Mautner VF, *et al.* (2007) Germline *NF1* mutational spectra and loss-of-heterozygosity analyses in patients with pheochromocytoma and neurofibromatosis type 1. *J Clin Endocrinol Metab* 92:2784–2792.
- Carey JC, Viskochil DH (1999) Neurofibromatosis type 1: A model condition for the study of the molecular basis of variable expressivity in human disorders. *Am J Med Genet* 89:7–13.

- Chilamakuri CS, Lorenz S, Madoui MA, *et al.* (2014) Performance comparison of four exome capture systems for deep sequencing. *BMC Genomics* 15:449.
- Chin E, Zhang V, Wang J, *et al.* (2013) Frequently asked questions about the clinical utility of next-generation sequencing in molecular diagnosis of human genetic diseases. In: Wong L-JC (ed) *Next Generation Sequencing: Translation to Clinical Diagnostics*. Springer Science+Business Media, New York, pp 287–299.
- Chun S, Fay JC (2009) Identification of deleterious mutations within three human genomes. *Genome Res* 19:1553–1561.
- Cingolani P, Platts A, Wang le L, *et al.* (2012) A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of *Drosophila melanogaster* strain w¹¹¹⁸; iso-2; iso-3. *Fly* 6:80–92.
- Cooper DN, Ball EV, Krawczak M (1998) The human gene mutation database. *Nucleic Acids Res* 26:285–287.
- De Luca A, Bottillo I, Dasdia MC, *et al.* (2007) Deletions of *NF1* gene and exons detected by multiplex ligation-dependent probe amplification. *J Med Genet* 44:800–808.
- Fahsold R, Hoffmeyer S, Mischung C, *et al.* (2000) Minor lesion mutational spectrum of the entire *NF1* gene does not explain its high mutability but points to a functional domain upstream of the GAP-related domain. *Am J Hum Genet* 66:790–818.
- Frommolt P, Abdallah AT, Altmüller J, *et al.* (2012) Assessing the enrichment performance in targeted resequencing experiments. *Hum Mutat* 33:635–641.
- Gasparini P, D'Agruma L, Pio de Cillis G, *et al.* (1996) Scanning the first part of the neurofibromatosis type 1 gene by RNA-SSCP: identification of three novel mutations and of two new polymorphisms. *Hum Genet* 97:492–495.
- Han SS, Cooper DN, Upadhyaya MN (2001) Evaluation of denaturing high performance liquid chromatography (DHPLC) for the mutational analysis of the neurofibromatosis type 1 (*NF1*) gene. *Hum Genet* 109:487–497.
- Hattori M, Torii C, Yagihashi T, *et al.* (2009) Diagnosis of Russell-Silver syndrome by the combined bisulfite restriction analysis—denaturing high-performance liquid chromatography assay. *Genet Test Mol Biomarkers* 13:623–630.
- Japanese Genetic Variation Consortium (2013) Human genetic variation browser. Available at www.genome.med.kyoto-u.ac.jp/SnpDB (accessed March 18 2014).
- Jones K (2005) *Smith's Recognizable Patterns of Human Malformation*. Saunders, Philadelphia.
- Kosaki K, Uda T, Okuyama T (2005) DHPLC in clinical molecular diagnostic services. *Mol Genet Metab* 86:117–123.
- Kumar P, Henikoff S, Ng PC (2009) Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. *Nat Protoc* 4:1073–1081.
- Lee MJ, Su YN, You HL, *et al.* (2006) Identification of forty-five novel and twenty-three known *NF1* mutations in Chinese patients with neurofibromatosis type 1. *Hum Mutat* 27:832.
- Li H, Durbin R (2009) Fast and accurate short read alignment with Burrows-Wheeler Transform. *Bioinformatics* 25:1754–1760.
- Li Y, Bollag G, Clark R, *et al.* (1992) Somatic mutations in the neurofibromatosis 1 gene in human tumors. *Cell* 69:275–281.
- McKenna A, Hanna M, Banks E, *et al.* (2010) The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Res* 20:1297–1303.
- Messiaen LM, Callens T, Mortier G, *et al.* (2000) Exhaustive mutation analysis of the *NF1* gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects. *Hum Mutat* 15:541–555.
- Nemethova M, Bolcekova A, Ilencikova D, *et al.* (2013) Thirty-nine novel neurofibromatosis 1 (*NF1*) gene mutations identified in Slovak patients. *Ann Hum Genet* 77:364–379.
- Neurofibromatosis Conference Statement (1988) National Institutes of Health Consensus Development Conference. *Arch Neurol* 45:575–578.
- Purandare SM, Huntsman Breidenbach H, *et al.* (1995) Identification of neurofibromatosis 1 (*NF1*) homologous loci by direct sequencing, fluorescence *in situ* hybridization, and PCR amplification of somatic cell hybrids. *Genomics* 30:476–485.
- Purandare SM, Lanyon WG, Connor JM (1994) Characterisation of inherited and sporadic mutations in neurofibromatosis type-1. *Hum Mol Genet* 3:1109–1115.
- Richards CS, Bale S, Bellissimo DB, *et al.* (2008) ACMG recommendations for standards for interpretation and reporting of sequence variations: revisions 2007. *Genet Med* 10:294–300.
- Rozen S, Skaletsky H (2000) Primer3 on the www for general users and for biologist programmers. *Methods Mol Biol* 132:365–386.
- Sabbagh A, Pasmant E, Imbard A, *et al.* (2013) *NF1* molecular characterization and neurofibromatosis type I genotype-phenotype correlation: the French experience. *Hum Mutat* 34:1510–1518.
- Samejima H, Torii C, Kosaki R, *et al.* (2007) Screening for Alagille syndrome mutations in the *JAG1* and *NOTCH2* genes using denaturing high-performance liquid chromatography. *Genet Test Mol Biomarkers* 11:216–227.
- Schwarz JM, Rödelberger C, Schuelke M, *et al.* (2010) MutationTaster evaluates disease-causing potential of sequence alterations. *Nat Methods* 7:575–576.
- Siepel A, Pollard KS, Haussler D (2009) New methods for detecting lineage-specific selection. *Proceedings of the 10th International Conference on Research in Computational. Mol Biol* 3909:190–205.
- Takenouchi T, Hida M, Sakamoto Y, *et al.* (2013a) Severe congenital lipodystrophy and a progeroid appearance: mutation in the penultimate exon of *FBN1* causing a recognizable phenotype. *Am J Med Genet A* 161A:3057–3062.
- Takenouchi T, Matsuzaki Y, Torii C, *et al.* (2014) *SOX9* dimerization domain mutation mimicking type 2 collagen disorder phenotype. *Eur J Med Genet* 57:298–301.
- Takenouchi T, Shimizu A, Torii C, *et al.* (2013b) Multiple Café au Lait spots in familial patients with *MAP2K2* mutation. *Am J Med Genet A* 164A:392–396.
- Teer JK, Green ED, Mullikin JC, *et al.* (2012) VarSifter: visualizing and analyzing exome-scale sequence variation data on a desktop computer. *Bioinformatics* 28:599–600.
- Thorvaldsdóttir H, Robinson JT, Mesirov JP (2013) Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. *Brief Bioinform* 14:178–192.
- Uda T, Imoto I, Aizu Y, *et al.* (2007) Multiplex PCR/liquid chromatography assay for screening of subtelomeric rearrangements. *Genet Test Mol Biomarkers* 11:241–248.
- Uda T, Kurosawa K, Izumi K, *et al.* (2006) Screening for partial deletions in the *CREBBP* gene in Rubinstein-Taybi syndrome patients using multiplex PCR/liquid chromatography. *Genet Test Mol Biomarkers* 10:265–271.
- Uda T, Torii C, Takahashi D, *et al.* (2005) Comprehensive screening of the thiopurine methyltransferase polymorphisms by denaturing high-performance liquid chromatography. *Genet Test Mol Biomarkers* 9:85–92.

- Upadhyaya M (2008) *NF1* gene structure and *NF1* genotype/phenotype correlations. In: Kaufmann D (ed) Neurofibromatoses. Karger, Basel, pp 46–62.
- Valero MC, Martín Y, Hernández-Imaz E, *et al.* (2011) A highly sensitive genetic protocol to detect NF1 mutations. *J Mol Diagn* 13:113–122.
- Yan D, Tekin M, Blanton SH, *et al.* (2013) Next-generation sequencing in genetic hearing loss. *Genet Test Mol Biomarkers* 17:581–587.

Address correspondence to:
Kenjiro Kosaki, MD, FACMG
Center for Medical Genetics
Keio University School of Medicine
35 Shinanomachi, Shinjuku-ku
Tokyo 160-8582
Japan
E-mail: kkosaki@z3.keio.jp